Stryker Corp
NYSE:SYK

Watchlist Manager
Stryker Corp Logo
Stryker Corp
NYSE:SYK
Watchlist
Price: 384.85 USD -1.36% Market Closed
Market Cap: 146.7B USD
Have any thoughts about
Stryker Corp?
Write Note

Stryker Corp
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Stryker Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Stryker Corp
NYSE:SYK
Cash & Cash Equivalents
$3.9B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
11%
Becton Dickinson and Co
NYSE:BDX
Cash & Cash Equivalents
$1.7B
CAGR 3-Years
-9%
CAGR 5-Years
26%
CAGR 10-Years
-1%
Boston Scientific Corp
NYSE:BSX
Cash & Cash Equivalents
$2.5B
CAGR 3-Years
9%
CAGR 5-Years
55%
CAGR 10-Years
26%
Edwards Lifesciences Corp
NYSE:EW
Cash & Cash Equivalents
$3.7B
CAGR 3-Years
35%
CAGR 5-Years
25%
CAGR 10-Years
25%
Abbott Laboratories
NYSE:ABT
Cash & Cash Equivalents
$7B
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash & Cash Equivalents
$2.4B
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
17%
No Stocks Found

Stryker Corp
Glance View

Market Cap
146.7B USD
Industry
Health Care

Stryker Corporation, a prominent player in the global medical technology landscape, has carved out a reputation for innovation and reliability since its founding in 1941. Specializing in developing and manufacturing a diverse range of products, Stryker's offerings span surgical equipment, implantable devices, and medical instruments, all designed to enhance patient care and improve clinical outcomes. Fueled by a commitment to quality and continuous improvement, the company invests heavily in research and development, leading the way with cutting-edge technologies like robotic surgical systems and advanced orthopedic solutions. The company’s strong market position is bolstered by its strategic acquisitions, which not only expand its product portfolio but also deepen its penetration into key medical segments, allowing Stryker to sustain impressive growth rates. For investors, Stryker represents a compelling opportunity in the healthcare sector, driven by the increasing demand for advanced medical solutions in an aging global population. With a presence in over 100 countries, Stryker's diversified revenue streams reduce risk and enhance resilience against market fluctuations. The company consistently delivers solid financial performance, characterized by robust margins and healthy cash flows, which it strategically reinvests to fuel future growth. Furthermore, its strong commitment to sustainability and corporate responsibility positions Stryker favorably in a market increasingly concerned with ethical practices. As the healthcare industry continues to evolve, Stryker’s innovative edge and solid fundamentals make it a captivating prospect for investors seeking long-term stability and growth.

SYK Intrinsic Value
287.61 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Stryker Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.9B USD

Based on the financial report for Sep 30, 2024, Stryker Corp's Cash & Cash Equivalents amounts to 3.9B USD.

What is Stryker Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
11%

Over the last year, the Cash & Cash Equivalents growth was 107%. The average annual Cash & Cash Equivalents growth rates for Stryker Corp have been 15% over the past three years , 15% over the past five years , and 11% over the past ten years .

Back to Top